Tissue Engineering Devices and Methods for Luminal Organs
Tissue engineering devices and methods are provided for the reconstruction, repair, augmentation, or replacement of a luminal organ or tissue structure involving the use of a biodegradable polymer matrix conforming to a portion of a laminarly arranged luminal organ, the processing of autologous, allogeneic or xenogeneic tissue comprising multiple cell populations to obtain a minced tissue composition, the seeding of the matrix with the composition, and the implanting of the seeded polymer matrix into a patient.
1 . An organ reconstruction method comprising the steps of:
providing a biodegradable polymer matrix conforming to a portion of a laminarly arranged luminal organ;
obtaining autologous, allogeneic or xenogeneic tissue comprising multiple cell populations;
processing the tissue to obtain a minced tissue composition;
seeding the matrix with the composition; and
implanting into a patient the seeded polymer matrix.
2 . The method of claim 1 further comprising the step of adding one or more matrix-digesting enzymes to said minced tissue composition.
3 . The method of claim 2 wherein said matrix-digesting enzyme is selected from the group consisting of collagenase, chondroitinase, trypsin, elastase, hyaluronidase, peptidase, thermolysin, protease, and combinations thereof.
4 . The method of claim 1 further comprising the step of adding one or more pharmaceuticals to said minced tissue composition.
5 . The method of claim 4 wherein said pharmaceutical is selected from the group consisting of antibiotics, antiviral agents, chemotherapeutic agents, anti-rejection agents, analgesics, anti-inflammatory agents, hormones, steroids, growth factors, naturally derived proteins, genetically engineered proteins, polysaccharides, glycoproteins, lipoproteins, and combinations thereof.
6 . The method of claim 1 further comprising the step of adding one or more pharmaceuticals to said polymer matrix.
7 . The method of claim 6 wherein said pharmaceutical is selected from the group consisting of antibiotics, antiviral agents, chemotherapeutic agents, anti-rejection agents, analgesics, anti-inflammatory agents, hormones, steroids, growth factors, naturally derived proteins, genetically engineered proteins, polysaccharides, glycoproteins, lipoproteins, and combinations thereof.
8 . The method of claim 1 further comprising the step of adding one or more stem cells to said minced tissue composition.
9 . An organ reconstruction method comprising the steps of:
providing a biodegradable polymer matrix conforming to a portion of a laminarly arranged luminal organ;
obtaining autologous, allogeneic or xenogeneic tissue comprising multiple cell populations;
processing the tissue to obtain a first minced tissue composition and a second minced tissue composition;
seeding a first area of the matrix with the first minced tissue composition, and seeding a second area of the matrix with the second minced tissue composition; and
implanting into a patient the seeded polymer matrix.
10 . The method of claim 9 wherein said first minced tissue composition is comprised of a smooth muscle tissue and said second minced tissue composition is comprised of an endothelial tissue.
11 . The method of claim 9 further comprising the step of adding one or more matrix-digesting enzymes to one or more minced tissue compositions.
12 . The method of claim 11 wherein said matrix-digesting enzyme is selected from the group consisting of collagenase, chondroitinase, trypsin, elastase, hyaluronidase, peptidase, thermolysin, protease, and combinations thereof.
13 . The method of claim 9 further comprising the step of adding one or more stem cells to one or more minced tissue compositions.
14 . An organ reconstruction device comprising an implantable, biodegradable polymer matrix conforming to a portion of a laminarly arranged luminal organ, wherein said matrix is capable of being seeded with a processed tissue composition, which comprises minced autologous, allogeneic or xenogeneic tissue comprising multiple cell populations.
15 . The device of claim 14 further comprising a polymer mesh fabric.
16 . The device of claim 14 further comprising a one or more pharmaceuticals.
17 . The device of claim 16 wherein said pharmaceutical is selected from the group consisting of antibiotics, antiviral agents, chemotherapeutic agents, anti-rejection agents, analgesics, anti-inflammatory agents, hormones, steroids, growth factors, naturally derived proteins, genetically engineered proteins, polysaccharides, glycoproteins, lipoproteins, and combinations thereof.
18 . A reinforced organ reconstruction device comprising an implantable, biocompatible polymer mesh having a first surface and a second surface, further having a first biodegradable polymer matrix in contact with said first polymer mesh surface, and further having a second biodegradable polymer matrix in contact with said second polymer mesh surface, wherein said polymer matrix-mesh-matrix construct is conforming to a portion of a laminarly arranged luminal organ, and further wherein said first and second polymer matrices are capable of being seeded with a processed tissue composition, which comprises minced autologous, allogeneic or xenogeneic tissue comprising multiple cell populations.
19 . The device of claim 18 further comprising a pharmaceutical.
20 . The device of claim 19 wherein said pharmaceutical is selected from the group consisting of antibiotics, antiviral agents, chemotherapeutic agents, anti-rejection agents, analgesics, anti-inflammatory agents, hormones, steroids, growth factors, naturally derived proteins, genetically engineered proteins, polysaccharides, glycoproteins, lipoproteins, and combinations thereof.